• Waldenström Macroglobulinemia
  • Melanoma
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Childhood Cancers
  • Gastric Cancer
  • Gynecologic Cancer
  • Head & Neck Cancer
  • Immunotherapy
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma Cancer
  • Mesothelioma
  • MPN
  • MDS
  • Myeloma
  • Prostate Cancer
  • Rare Cancers
  • Sarcoma
  • Skin Cancer
  • Testicular Cancer
  • Thyroid Cancer

Expert Hopes to See New Drug Combinations for MPNs in 2024

News
Article

Dr. Lucia Masarova sat down with CURE® and discussed the advancements she hopes to see in 2024 for the treatment of patients with myeloproliferative neoplasms.

While there have been many exciting advancements for the treatment of myeloproliferative neoplasms (MPNs) in 2023, Dr. Lucia Masarova, is hoping to see continued exploration of non-JAK inhibitors and other drug combinations in 2024.

“I'm looking forward to see how we're going to define to use of non-JAK drugs to combinations to see whether we're going to be able to come up with a plan to combine other JAK inhibitors,” Masarova, who is a member of the department of Leukemia, division of Cancer Medicine at The Unviersity of Texas MD Anderson Cancer Center, said in an interview with CURE® at the 2023 American Society of Hematology Annual Meeting.

JAK inhibitors, such as Jakafi (ruxolitinib) work by blocking the JAK-STAT pathway, which is regulates how the bone marrow produces blood cells. While Jakafi improves symptoms and quality of life — including reducing spleen volume — there is still no cure for this patient population.

READ MORE: One Step Closer to an MPN Cure

Transcript

I'm looking forward to see how we're going to define to use of non-JAK drugs and combinations to see whether we're going to be able to come up with a plan to combine other JAK inhibitors. Particularly they are the last myelosuppressive. So that'll open space in this area. Hopefully we'll find out how other drugs could work for the accelerated phase that could be combined with any agents we have there in my light field to finally start exploring that in a more kind of consistent fashion.


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
A man with a dark gray button-up shirt with glasses and cropped brown hair.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Kim in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content